Ocular tear growth factor-like protein
CA 2438334 C · Owner: Laurie, Gordon W. · Inventors: Lumsden, Angela J.; Laurie, Gordon W.; Sanghi, Sandhya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly one embodiment of the , present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 2002 and granted July 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.